128
Participants
Start Date
October 31, 2004
Primary Completion Date
September 30, 2006
Study Completion Date
September 25, 2006
Dihydrotestosterone (0.7%) in hydroalcoholic gel
transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Bethesda Health Research, Bethesda
Johns Hopkins University, Baltimore
McGuire VA Medical Center, Richmond
Duke University Medical Center, Durham
Pensacola Research Consultants, Pensacola
Malcom Randall VA Medical Center, Gainesville
Genesis Research Consultants, Longwood
University of Louisville, Louisville
North Indiana Research, Fort Wayne
VA Medical Center, Houston
Radiant Research - San Antonio, San Antonio
University of Utah School of Medicine, Salt Lake City
Radiant Research - Phoenix, Phoenix
Harbor UCLA Medical Reserach and Education Institute, Torrance
Oregon Health Sciences Center, Portland
VA Puget Sound Health Care, Seattle
Lead Sponsor
ASCEND Therapeutics
INDUSTRY